Anita Shaffer


NCCN Guidelines Reflect Recent Advances in Resectable NSCLC

June 02, 2022

Updates to the NCCN guidelines for patients with resectable early-stage NSCLC now include neoadjuvant and adjuvant regimens with chemotherapy, immunotherapy, and targeted therapies, which promise to change biomarker testing practice.

FDA to Reassess Accelerated Immunotherapy Approvals

March 12, 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

Shorter Adjuvant Chemo in Colon Cancer Is Effective, Reduces Neuropathy Risk

June 05, 2017

According to findings presented at the 2017 ASCO Annual Meeting, patients with low-risk advanced colon cancer would benefit from a reduction in chemotherapy post-surgery, without increasing risk of recurrence, to reduce risk of neuropathy.